Program
sulthiame
Its studies are mostly in Renal Insufficiency · Sleep Apnea, Obstructive, led by 2 companies.
Drug pageSulthiame: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Desitin Arzneimittelits history only | 10 open or running | phase 2since Jan 20, 2022 | Jan 20, 2022 | none ahead |
| Shionogi | 11 open or running | phase 1since Sep 29, 2026 | Sep 29, 2026 | Dec 4, 2026phase 1 · NCT07857837 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Shionogi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 29, 2026First study: phase 1 study in Renal InsufficiencyFirst studyNCT07857837 · 30 planned · United States
Ahead
- Dec 4, 2026Primary completion: phase 1 study in Renal InsufficiencyNCT07857837
TargetBeta
“Carbonic anhydrase inhibitor”ChEMBL 37, by rule
Studies
The one study Shionogi leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07857837Renal Insufficiency · United States | 1 | Not yet recruiting | Dec 4, 2026 | 30 |
How it is read
Names in the registry
- “Sulthiame”, 2 entries
Conditions, from the studies’ own filings
- Renal Insufficiency, 1 study
- Sleep Apnea, Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.